Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer.

Modur V, Nagarajan R, Evers BM, Milbrandt J.

J Biol Chem. 2002 Dec 6;277(49):47928-37. Epub 2002 Sep 25.

2.

Regulation of sensitivity to TRAIL by the PTEN tumor suppressor.

Whang YE, Yuan XJ, Liu Y, Majumder S, Lewis TD.

Vitam Horm. 2004;67:409-26. Review.

PMID:
15110188
3.
4.

APO2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in prostate cancer therapy.

Bucur O, Ray S, Bucur MC, Almasan A.

Front Biosci. 2006 May 1;11:1549-68. Review.

PMID:
16368536
5.

The role of PTEN in the progression and survival of prostate cancer.

Deocampo ND, Huang H, Tindall DJ.

Minerva Endocrinol. 2003 Jun;28(2):145-53. Review.

PMID:
12717346
6.

PTEN regulatory functions in tumor suppression and cell biology.

Chu EC, Tarnawski AS.

Med Sci Monit. 2004 Oct;10(10):RA235-41. Epub 2004 Sep 23. Review.

PMID:
15448614
7.

The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy.

Mills GB, Lu Y, Fang X, Wang H, Eder A, Mao M, Swaby R, Cheng KW, Stokoe D, Siminovitch K, Jaffe R, Gray J.

Semin Oncol. 2001 Oct;28(5 Suppl 16):125-41. Review.

PMID:
11706404
8.

Akt, FoxO and regulation of apoptosis.

Zhang X, Tang N, Hadden TJ, Rishi AK.

Biochim Biophys Acta. 2011 Nov;1813(11):1978-86. doi: 10.1016/j.bbamcr.2011.03.010. Epub 2011 Mar 31. Review.

9.

FOXO transcription factors in cancer development and therapy.

Coomans de Brachène A, Demoulin JB.

Cell Mol Life Sci. 2016 Mar;73(6):1159-72. doi: 10.1007/s00018-015-2112-y. Epub 2015 Dec 19. Review.

PMID:
26686861
10.

Molecular mechanisms of prostate cancer.

Porkka KP, Visakorpi T.

Eur Urol. 2004 Jun;45(6):683-91. Review.

PMID:
15149739
11.

Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment.

De Marzo AM, DeWeese TL, Platz EA, Meeker AK, Nakayama M, Epstein JI, Isaacs WB, Nelson WG.

J Cell Biochem. 2004 Feb 15;91(3):459-77. Review.

PMID:
14755677
12.

Apoptosis in prostate cancer: progressive and therapeutic implications (Review).

Wang G, Reed E, Li QQ.

Int J Mol Med. 2004 Jul;14(1):23-34. Review.

PMID:
15202013
13.

FoxO family members in cancer.

Zhang Y, Gan B, Liu D, Paik JH.

Cancer Biol Ther. 2011 Aug 15;12(4):253-9. Epub 2011 Aug 15. Review.

PMID:
21613825
14.

Regulation of the FoxO family of transcription factors by phosphatidylinositol-3 kinase-activated signaling.

Arden KC, Biggs WH 3rd.

Arch Biochem Biophys. 2002 Jul 15;403(2):292-8. Review. No abstract available.

PMID:
12139979
15.

FOXO transcription factors as regulators of immune homeostasis: molecules to die for?

Birkenkamp KU, Coffer PJ.

J Immunol. 2003 Aug 15;171(4):1623-9. Review.

16.

Molecular genetics of prostate cancer.

Elo JP, Visakorpi T.

Ann Med. 2001 Mar;33(2):130-41. Review.

PMID:
11327116
17.

Autophagy process is associated with anti-neoplastic function.

Wang C, Wang Y, McNutt MA, Zhu WG.

Acta Biochim Biophys Sin (Shanghai). 2011 Jun;43(6):425-32. doi: 10.1093/abbs/gmr028. Epub 2011 Apr 26. Review.

PMID:
21525017
18.

The "O" class: crafting clinical care with FoxO transcription factors.

Maiese K, Chong ZZ, Hou J, Shang YC.

Adv Exp Med Biol. 2009;665:242-60. Review.

19.

The many forks in FOXO's road.

Tran H, Brunet A, Griffith EC, Greenberg ME.

Sci STKE. 2003 Mar 4;2003(172):RE5. Review.

PMID:
12621150
20.

Methodological aspects of the molecular and histological study of prostate cancer: focus on PTEN.

Ugalde-Olano A, Egia A, Fernández-Ruiz S, Loizaga-Iriarte A, Zuñiga-García P, Garcia S, Royo F, Lacasa-Viscasillas I, Castro E, Cortazar AR, Zabala-Letona A, Martín-Martín N, Arruabarrena-Aristorena A, Torrano-Moya V, Valcárcel-Jiménez L, Sánchez-Mosquera P, Caro-Maldonado A, González-Tampan J, Cachi-Fuentes G, Bilbao E, Montero R, Fernández S, Arrieta E, Zorroza K, Castillo-Martín M, Serra V, Salazar E, Macías-Cámara N, Tabernero J, Baselga J, Cordón-Cardo C, Aransay AM, Villar AD, Iovanna JL, Falcón-Pérez JM, Unda M, Bilbao R, Carracedo A.

Methods. 2015 May;77-78:25-30. doi: 10.1016/j.ymeth.2015.02.005. Epub 2015 Feb 16. Review.

Supplemental Content

Support Center